News > News Archive
Civitas Therapeutics, Inc. Plans Phase 2b Study of CVT-301, Inhaled L-dopa for Parkinson's Disease
Civitas Therapeutics, Inc. is initiating further clinical study of CVT-301, an inhaled formulation of levodopa. CVT-301 is being developed as an adjunct therapy that will provide rapid and reliable relief from intermittent debilitating motor fluctuations (OFF episodes) that affect many Parkinson’s disease patients. This Phase 2 study will evaluate the efficacy and safety of CVT-301 in treating emergent OFF episodes.
The Michael J. Fox Foundation for Parkinson’s Research used its 2012 research grant from the Parkinson’s Unity Walk to help fund this project. Read more…
Go to earlier archived stories